In a pooled analysis, the use of Dupilumab, with or without topical corticosteroids, was associated with improvements in signs, symptoms, and quality of life of adults (≥ 60 years of age) suffering from atopic dermatitis. These results were consistent with those in patients younger than 60 years of age. The objective was to assess Dupilumab's safety and effectiveness to combat atopic dermatitis.

Data were combined and stratified by age (< 60 [N = 2261] and ≥ 60 [N = 183] years) from 4 randomized, placebo-controlled Dupilumab trials of people suffering from moderate-to-severe atopic dermatitis (LIBERTY AD CHRONOS, LIBERTY AD CAFÉ, LIBERTY AD SOLO 1 and 2).

Participants either got a placebo or 300 mg of Dupilumab every week (qw) or every two weeks (q2w) with or without topical corticosteroids. With the aid of extensive categorical and continuous evaluations of skin lesions, symptoms, biomarkers, and quality of life, post hoc effectiveness at week 16 was assessed. Safety was also examined.

At week 16, more Dupilumab-treated patients in the  ≥ 60-year group had an Investigator's Global Assessment (IGA) score of 0/1 (q2w: 44.4%; qw: 39.7%), and their Eczema Area and Severity Index (EASI) had improved by 75% (q2w: 63.0%; qw: 61.6%) compared to placebo (q2w: 7.1%; qw: 14.3%). Immunoglobulin E, thymus- and activation-regulated chemokines, which are type 2 inflammatory indicators, were also considerably decreased in Dupilumab-treated patients compared to placebo-treated patients.

In the < 60-year-old group, the results were comparable. The exposure-adjusted rates of adverse events in patients receiving Dupilumab were usually comparable to patients receiving placebo, with statistically fewer treatment-emergent adverse events in the Dupilumab-treated ≥ 60-year-old group compared to placebo. Dupilumab led to improvements in atopic dermatitis signs and symptoms in people aged ≥ 60 years. The results were analogous to those in patients aged less than 60 years. The safety findings illustrated consistency with Dupilumab's established safety profile.